In February, Dr. Turnier and Dr. Sabbagh presented an informational Town Hall for JM families. Catch It Early, Control It Faster: Discover expert tips for spotting and navigating Juvenile Dermatomyositis (JDM) flares for better control and brighter outcomes
Vamorolone FAQs in JM
With the looming FDA approval of the drug vamorolone in Duchenne muscular dystrophy, there are questions surrounding the drug’s status for trials in juvenile myositis. We have consulted with JM experts on the potential implications of a pending approval for the drug in another disease and what this currently means for JM patients living in the U.S.
